Contezolid

Synonyms: MRX-I
Contezolid (MRX-I) 是一种新型恶唑烷酮类抗生素,用于治疗耐药革兰氏阳性菌引起的皮肤软组织感染并发症 (cSSTI),并可显著降低骨髓抑制和单胺氧化酶抑制作用。
产品编号: MS-L22425 纯度: 99.21% CAS No.: 1112968-42-9 分子式: C18H15F3N4O4 分子量: 408.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Contezolid (MRX-I) 是一种新型恶唑烷酮类抗生素,用于治疗耐药革兰氏阳性菌引起的皮肤软组织感染并发症 (cSSTI),并可显著降低骨髓抑制和单胺氧化酶抑制作用。

生物实验数据

生物活性 Contezolid (MRX-I) is a novel oxazolidinone antibiotic used for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria, and it significantly reduces bone marrow suppression and monoamine oxidase inhibition.
IC50 & Target

Oxazolidinone

 

体外研究
(In Vitro)

Contezolid (MRX-I) is highly potent against all Grampositive clinical isolates of staphylococci, streptococci, and enterococci, including MDR organisms such as MRSA, methicilline-resistant Streptococcus epidermidis (MRSE), penicillin-resistant Streptococci (PRSP), and VRE.

体内研究
(In Vivo)

Oral absorption of Contezolid (MRX-I) occurrs rapidly in mouse, rat, and dog, with peak plasma concentrations observed at 0.5−2.6 h postdose. In mouse, rat, and dog, respectively, PK parameters are determined as follows: dose-normalized Cmax/dose was 524, 1065, and 259 ng/mL/(mg/kg); dose-normalized AUC0−t/dose was 1654, 3703, and 1664 ng•h/mL/(mg/kg); T1/2 is 1, 1.5, and 3 h; and the oral bioavailability is 69%, 109%, and 37%.
Contezolid (MRX-I) exhibits no obvious toxicity.
Contezolid (MRX-I, 100 mg/kg, once daily) significantly reduced the bacterial load in lungs compared to the untreated early and late controls.

Animal Model: BALB/c mice infected intranasally with M. tuberculosis Erdman.
Dosage: 100, 50 (twice), 25 (twice) mg/kg.
Administration: Gavage, once or twice daily, five days per week for four weeks.
Result: Significantly reduced the CFU recovered from the lungs compared to the early and late control mice (P < 0.05).
Twice daily MRX-I at 50mg/kg and 25 mg/kg were significantly better than the late control mice (P < 0.05).
Once daily MRX-I at 100 mg/kg was significantly better than twice daily 50 mg/kg and 25 mg/kg (P < 0.05). There was no statistical difference between twice daily 50 mg/kg of MRX-I and 25mg/kg (P > 0.05).
Animal Model: Rats.
Dosage: 20, 100, and 200/300 mg/kg/day.
Administration: Orally twice daily.
Result: No mortality was observed.
性状 固体
颜色 White to light yellow

化学信息

分子量 408.33
分子式 C18H15F3N4O4
CAS No. 1112968-42-9
别名 MRX-I

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.8 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 120 mg/mL (293.88 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4490 mL12.2450 mL24.4900 mL61.2250 mL
5 mM0.4898 mL2.4490 mL4.8980 mL12.2450 mL
10 mM0.2449 mL1.2245 mL2.4490 mL6.1225 mL
15 mM0.1633 mL0.8163 mL1.6327 mL4.0817 mL
20 mM0.1224 mL0.6122 mL1.2245 mL3.0612 mL
25 mM0.0980 mL0.4898 mL0.9796 mL2.4490 mL
30 mM0.0816 mL0.4082 mL0.8163 mL2.0408 mL
40 mM0.0612 mL0.3061 mL0.6122 mL1.5306 mL
50 mM0.0490 mL0.2449 mL0.4898 mL1.2245 mL
60 mM0.0408 mL0.2041 mL0.4082 mL1.0204 mL
80 mM0.0306 mL0.1531 mL0.3061 mL0.7653 mL
100 mM0.0245 mL0.1224 mL0.2449 mL0.6122 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础